The head of the 48th Central research Institute of the troops of radiation, chemical and biological protection of armed forces of Russia, Colonel of medical service Sergey Borisevich told about the results of the vaccination of volunteers from COVID-19.
As the findings of the analyses of the second group of volunteers who participated in vaccine trials in the Main military clinical Burdenko hospital, as a result of vaccination “revealed the necessary antibodies to coronavirus, and the components of the vaccine safe and well tolerated by man”, writes “Krasnaya Zvezda”.
Borisevich said that the platform on which a vaccine is developed, gives the chance long-term to maintain a protective titer. On this platform have created a vaccine against Ebola and middle East respiratory syndrome, reports TASS.
Monday write out “second, the last group of volunteers consisting of 20 people.” Them 13 July, was introduced by the second component of the vaccine against coronavirus.
The vaccine was developed with the cooperation of the Ministry of defense of Russia and National research center of epidemiology and Microbiology named Gamalei.
Director of the Institute Gamalei Alexander Ginzburg stated that the vaccine for coronavirus infection can enter into circulation on 14-15 August. The second phase of the vaccine trials will last until 28 July, after which the Institute will apply for registration, which is expected to last until August 2-4.
